Log in to save to my catalogue
Log in to save to my catalogue

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer

| Ask | Become a Library member

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8967713

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer

About this item

Publication information

Publisher

London: Nature Publishing Group UK

Subjects

Subjects and topics

More information

Scope and Contents

Contents

Standard first-line chemotherapy results in disease progression and death within one year in most patients with human epidermal growth factor receptor 2 (HER2)-negative gastro-oesophageal adenocarcinoma
1
–
4
. Nivolumab plus chemotherapy demonstrated superior overall survival versus chemotherapy at 12-month follow-up in gastric, gastro...

Alternative Titles

Full title

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer

Authors, Artists and Contributors

Author / Creator

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8967713

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8967713

Other Identifiers

ISSN

0028-0836

E-ISSN

1476-4687

DOI

10.1038/s41586-022-04508-4

How to access this item

Log in as a Library member

Full text available

About resource

View in old catalogue

Connecting people and collections